Semaglutide reduces blood glucose levels through glucose-dependent stimulation of insulin secretion and suppression of glucagon secretion. Thus, insulin secretion is stimulated with increased blood glucose concentration, and glucagon secretion is suppressed. Lowering glycemic levels also includes a slight delay in gastric emptying in the early postprandial phase. During hypoglycemia, semaglutide reduces insulin secretion and does not reduce glucagon secretion.
Semaglutide reduces total body weight and adipose tissue mass by lowering energy intake. This mechanism involves a general decrease in appetite, including an increase in satiety signals and a reduction of hunger signals, as well as improved control of food intake and decreased food cravings. Insulin resistance is also reduced, possibly due to weight loss. In addition, semaglutide reduces the preference for high-fat meals.
Semaglutide is a weight management drug that comes as a solution for weekly injections. The drug inhibits patients’ appetite and helps them lose about 15% of their body weight.
